LEQEMBI Pen approved in Japan for early Alzheimer’s
Eisai and Biogen said Japan approved LEQEMBI Pen, the subcutaneous formulation of lecanemab, for early Alzheimer’s disease treatment.
TOKYO and CAMBRIDGE, Mass., Sept 18, 2026 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB), announced today that "LEQEMBI(R) Pen", the subcutaneous (SC) formulation of the anti-amyloid beta (AB) protofibril antibody "LEQEMBI(R)" (brand name, generic name: lecanemab) has been approved in Japan for the treatment of early Alzheimer's disease.